Rocket


Overview
Financials
News + Filings
Key Docs
Charts
Ownership
Insiders


All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Inv. presentation
Quarterly results
Sana Biotechnology, Inc. (SANA) Create: Alert

All | News | Filings
Date FiledTypeDescription
10/10/2023 8-K Quarterly results
08/21/2023 8-K Termination of a Material Definitive Agreement  Interactive Data
08/03/2023 8-K Quarterly results
Docs: "Sana Biotechnology Reports Second Quarter 2023 Financial Results and Business Updates Enrolling patients in ARDENT, the SC291 Phase 1 clinical trial in B-cell malignancies, with initial data expected this year Expect data later this year from investigator-sponsored trial with hypoimmune-modified primary human islet cells Goal to submit INDs this year for both SC262 and SG299 in hematologic cancers Hosted R&D Day, showcasing broad portfolio across platforms, programs, and diseases Announced plan to develop SC291 in autoimmune disorders Shared preclinical data that transplanted allogeneic hypoimmune-modified islet cells evade rejection and control glucose without immunosuppression or insulin treatment in non-human primate diabetes study Data published in Science Translational Medicine, Natur..."
06/09/2023 8-K Submission of Matters to a Vote of Security Holders  Interactive Data
06/07/2023 8-K Investor presentation
Docs: "CAR 4 CD22 CD19 BCMA GPRC5D"
05/08/2023 8-K Quarterly results
Docs: "Sana Biotechnology Reports First Quarter 2023 Financial Results and Business Updates IND cleared and enrolling patients in SC291 Phase 1 clinical trial in B-cell malignancies with initial data expected later this year"
03/16/2023 8-K Quarterly results
Docs: "Sana Biotechnology Reports Fourth Quarter and Full Year 2022 Financial Results and Business Updates Announced SC291 IND clearance with goal to report initial clinical data this year"
01/26/2023 8-K Other Events, Financial Statements and Exhibits  Interactive Data
Docs: "Sana Biotechnology Announces FDA Clearance of Investigational New Drug Application for SC291, a Hypoimmune-modified, CD19-targeted Allogeneic CAR T Therapy for Patients with B-Cell Malignancies Goal is to report initial SC291 clinical data this year"
01/26/2023 8-K Other Events, Financial Statements and Exhibits  Interactive Data
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION",
"Sana Biotechnology Announces FDA Clearance of Investigational New Drug Application for SC291, a Hypoimmune-modified, CD19-targeted Allogeneic CAR T Therapy for Patients with B-Cell Malignancies"
01/10/2023 8-K Investor presentation
Docs: "Corporate Presentation"
11/29/2022 8-K Quarterly results
11/02/2022 8-K Quarterly results
11/01/2022 8-K Quarterly results
08/04/2022 8-K Quarterly results
06/14/2022 8-K Quarterly results
06/09/2022 8-K Quarterly results
06/01/2022 8-K Quarterly results
05/10/2022 8-K Quarterly results
03/16/2022 8-K Quarterly results
Docs: "Sana Biotechnology Reports Fourth Quarter and Full Year 2021 Financial Results and Business Updates Plans to present data at multiple scientific conferences in 2022"
01/11/2022 8-K Investor presentation
Docs: "Corporate Presentation",
"Sana Biotechnology Obtains Exclusive License from National Institutes of Health for CD22 CAR Construct License will enable Sana’s in vivo and ex vivo engineered T cell programs for B cell malignancies"
11/08/2021 8-K Quarterly results
Docs: "Sana Biotechnology Reports Third Quarter 2021 Financial Results and Business Updates Announced license agreement for Beam’s CRISPR Cas12b nuclease system for certain ex vivo engineered cell therapy programs Q3 2021 cash position of $866.1 million"
10/19/2021 8-K Entry into a Material Definitive Agreement, Other Events, Financial Statements and Exhibits  Interactive Data
Docs: "Sana Biotechnology Obtains a Non-Exclusive License to CRISPR Cas12b Gene Editing Technology from Beam Therapeutics to Enable Engineered Cell Programs Agreement combines Beam’s gene editing technology with Sana’s ex vivo platform"
09/13/2021 8-K Quarterly results
09/03/2021 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
08/04/2021 8-K Quarterly results
Docs: "Sana Biotechnology Reports Second Quarter 2021 Financial Results and Business Updates Presented data showing immune evasion and survival after transplantation of allogeneic cells into primates without immune suppression at ISSCR 2021"
07/14/2021 8-K Quarterly results
05/05/2021 8-K Quarterly results
03/24/2021 8-K Quarterly results
03/02/2021 8-K Quarterly results
02/09/2021 8-K Quarterly results

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy